For BRVO , there was a significant reduction from week @ mean BCVA in ranibizumab plus laser versus ranibizumab at week @ ( -@ vs. +@ ; P < @ ) and week @ ( -@ vs. +@ ; P < @ ) , but not week @ , and there were no differences in mean CST change from week @ at weeks @ , @ , or @ .